ENTAHealthcare · BiotechnologyThe 6 Wall Street analysts covering Enanta Pharmaceuticals, Inc. hold a median 12-month price target of $20 — +42.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Enanta Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (93): Sales and profits are climbing, and climbing faster than before.
Revisions (28): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ENTA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +42.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 10 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2025 | JP Morgan | Initiates | Overweight | — |
| 1 Oct 2025 | Jefferies | Upgrade | Buy | — |
| 30 Sept 2025 | WestPark Capital | Maintains | Buy | — |
| 15 Sept 2025 | Evercore ISI Group | Maintains | Outperform | — |
| 2 Sept 2025 | WestPark Capital | Initiates | Buy | — |
| 12 Aug 2025 | JMP Securities | Maintains | Market Outperform | — |
| 28 July 2025 | HC Wainwright & Co. | Assumes | Buy | $20 |
| 3 June 2025 | JMP Securities | Maintains | Market Outperform | — |
| 14 May 2025 | JMP Securities | Maintains | Market Outperform | — |
| 11 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Feb 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 24 Dec 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Nov 2024 | Baird | Maintains | Outperform | — |
| 26 Nov 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 10 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Oct 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 27 Sept 2024 | JMP Securities | Reiterates | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENTA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Enanta Pharmaceuticals, Inc. returned +59.5% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 22% of US stocks
Cheaper than 28% of US stocks
Cheaper than 81% of US stocks
Higher than 11% of US stocks
Higher than 13% of US stocks
Higher than 6% of US stocks
Higher than 17% of US stocks
Higher than 25% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Enanta Pharmaceuticals, Inc. has a market value of $392.3M and an enterprise value of $384.9M.
Revenue in the twelve months to 31 Mar 2026: $69.2M. The latest quarter shrank 21.6% year on year.
Net income over the same four quarters: −$62.0M, a −89.6% net margin.
Diluted earnings per share, trailing twelve months: $−2.59.
Free cash flow in the twelve months to 31 Mar 2026: −$9.6M, after $1.8M of capital spending.
Trailing P/E: −3.5×; forward P/E: −5.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Enanta Pharmaceuticals, Inc. employs 120 people — $577K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Enanta Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Enanta Pharmaceuticals reported a fiscal-third-quarter loss of $0.67 per share, which was wider than the Zacks Consensus Estimate of a $0.37 loss but narrower than the $0.85 per share loss a year earlier.
Why it matters — The quarterly results missed analyst revenue and earnings expectations, which ENTA watchers would note as a sign of weaker-than-projected performance.
Enanta Pharmaceuticals reported financial results for its fiscal third quarter ended June 30, 2026. The company noted continued momentum across its RSV and immunology programs, including the start of dosing in the LOTUS Phase trial.
Why it matters — A watcher of ENTA would care because the update highlights progress in the company's key clinical programs, including the initiation of the LOTUS trial.
The 6 Wall Street analysts covering Enanta Pharmaceuticals, Inc. have a median 12-month price target of $20, with estimates ranging from $19 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Enanta Pharmaceuticals, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enanta Pharmaceuticals, Inc. 87 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Enanta Pharmaceuticals, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +42.0% from the last close, and Ticker Nerd's factor model ranks Enanta Pharmaceuticals, Inc. 87 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Enanta Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $28 over the next 12 months.
Enanta Pharmaceuticals, Inc. returned +59.5% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Enanta Pharmaceuticals Inc. is a biotechnology company dedicated to the discovery and development of small molecule drugs.
The most recent item we track (Zacks Investment Research, 10 Aug 2026): "Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates". Enanta Pharmaceuticals reported a fiscal-third-quarter loss of $0.67 per share, which was wider than the Zacks Consensus Estimate of a $0.37 loss but narrower than the $0.85 per share loss a year earlier.
Enanta Pharmaceuticals Inc. is a biotechnology company dedicated to the discovery and development of small molecule drugs. The primary focus of the company is on creating innovative treatments for viral infections and liver diseases. Enanta has a proven track record in drug discovery, having developed lead candidates for hepatitis C virus (HCV), respiratory syncytial virus (RSV), and non-alcoholic steatohepatitis (NASH). Its strategic collaboration with major pharmaceutical companies has resulted in the successful commercialization of HCV treatments. The company's pipeline is rich with potential therapies targeting significant global health issues, maintaining a critical role in advancing medical breakthroughs. Enanta Pharmaceuticals is headquartered in Watertown, Massachusetts and operates in a highly competitive biotech sector, where it leverages deep expertise in medicinal chemistry and drug development to address unmet medical needs. Enanta's contribution to antiviral therapies reinforces its significance in the fast-evolving field of biotechnology.
CEO Dr. Jay R. Luly Ph.D. · 120 employees · United States · https://www.enanta.com
